Innovative Molecules GmbH, a biotechnology firm based in Munich, has partnered with Italian pharmaceutical company Alfasigma S.p.A. under a licensing agreement for the antiviral drug Adibelivir. The collaboration aims to advance the development and commercialization of the treatment.
Legal advisory services for Innovative Molecules were provided by Baker McKenzie during the formation of this partnership.
**Why this matters**
This agreement enables both companies to combine resources and expertise to accelerate the availability of Adibelivir. The partnership could enhance the drug’s reach in new markets, potentially benefiting patients requiring antiviral therapies.
Source: NewsData